Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LY3090106 - IV
LY3090106 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| LY3090106 | EXPERIMENTAL | LY3090106 given subcutaneously (SC) in escalating dose cohorts once every 2 or 4 weeks for 16 weeks. |
| Placebo | PLACEBO_COMPARATOR | Placebo given subcutaneously (SC) once every 2 or 4 weeks for 16 weeks. |
| Name | Type | Description |
|---|---|---|
| LY3090106 | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * Have a confirmed diagnosis of SS by the American-European Consensus Group criteria with active disease (at any level), as per judgment of the investigator (participants with another concurrent, stable connective tissue disease may be eligible for inclusion, with written approv...
Top 2 of 7 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Akebia Therapeutics, Inc. | AKBA | 1 | PHASE2 | Vadadustat |
| Rigel Pharmaceuticals, Inc. | RIGL | 1 | PHASE2 | Fostamatinib |
LY3090106 is an investigational small molecule being studied for the treatment of Sjögren's Syndrome, an autoimmune condition. It has been evaluated in a Phase 1 clinical trial in adults with the disease. It is not approved for any indication and remains in clinical development.
LY3090106 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly sponsored the Phase 1 study of the compound in participants with Sjögren's Syndrome.
LY3090106 is in Phase 1 clinical development. The single reported trial, NCT02614716, was a Phase 1 study in participants with Sjögren's Syndrome and is now completed. The drug is investigational and has not been approved by the FDA.
LY3090106 has been studied in one clinical trial, NCT02614716, titled A Study of LY3090106 in Participants With Sjögren's Syndrome. The Phase 1 trial enrolled 32 participants across the United States, Bulgaria, Georgia, and Romania and is completed.
Yes, LY3090106 - IV is an alternative name for LY3090106. Both refer to the same investigational small molecule developed by Eli Lilly and Company for Sjögren's Syndrome.
The Phase 1 trial NCT02614716 was a randomized, double-blind, placebo-controlled study of LY3090106 in 32 adults with Sjögren's Syndrome. Participants were 18 years or older, and the study enrolled across the United States, Bulgaria, Georgia, and Romania.